Program
Anti-TF Antibody-drug Conjugate MRG004A
Also written as “MRG004A” and “MRG004A plus best supportive care”.
Its studies are mostly in Pancreatic Neoplasms, led by Lepu Biopharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lepu Biopharma | 21 open or running | phase 3since Aug 17, 2025 | Apr 8, 2021 | Jun 2027phase 3 · NCT07138846 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 8, 2021First study: phase 2 study in Advanced or Metastatic Solid TumorsFirst studyNCT04843709 · 39 enrolled · United States, China
- Aug 17, 2025Phase 3 study in Pancreatic NeoplasmsNCT07138846 · 231 planned · China
Ahead
- Jun 2027Primary completion: phase 3 study in Pancreatic NeoplasmsNCT07138846
TargetBeta
“An antibody-drug conjugate (ADC) comprised of a monoclonal antibody against human tissue factor (TF) ”NCIt, by rule
Other programs on F3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tisotumab vedotinrule | Pfizer | phase 4 | 11 |
| Anti-TF/TOP1i Antibody-drug Conjugate XNW28012rule | Evopoint Biosciences | phase 3 | 3 |
| SHR-4375 | Jiangsu HengRui Medicine | phase 2 | 2 |
| Anti-TF/TOP1i Antibody-drug Conjugate XB371rule | Exelixis | phase 1 | 1 |
| Anti-TF/Exatecan Antibody-drug Conjugate STRO-004rule | sutro-biopharma-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07138846Pancreatic Neoplasms · China | 3 | Not yet recruiting | Jun 2027 | 231 |
| NCT04843709Advanced or Metastatic Solid Tumors · United States, China | 2 | Completed | Mar 20, 2024 | 39 |
How it is read
Names in the registry
- “MRG004A”, 1 entry
- “MRG004A plus best supportive care”, 1 entry
Codes read as this program: MRG004A.
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.